Results 11 to 20 of about 380,241 (292)
Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer [PDF]
Therapeutic Advances in Medical Oncology, 2020 Background: The introduction of antibodies targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) into clinical practice has had a revolutionary effect on cancer treatment.
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj +3 more sources
Frontiers in Immunology, 2023 BackgroundMultiple clinical studies have indicated that the gut microbiota influences the effects of immune checkpoint blockade (ICB) therapy comprising PD-1/PD-L1 inhibitors, but the causal relationship is unclear.
Yu-Feng Huang +9 more
doaj +3 more sources
Acta Dermato-Venereologica, 2021 Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors.
Aikaterini Tsiogka +2 more
doaj +3 more sources
Frontiers in Pharmacology, 2022 Neuroendocrine carcinoma of the cervix (NECC) is a highly aggressive and rare gynecological malignancy with a poor prognosis. Despite aggressive local and systemic treatments, there are high rates of locoregional recurrence and distant metastases ...
Rongyu Liu +5 more
doaj +3 more sources
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]
Critical Care, 2018 Debasree Banerjee +7 more
doaj +3 more sources
Gut Microbiota Modulates the Efficiency of Programmed Cell Death Protein 1 Cancer Immunotherapies
Iranian Journal of Allergy, Asthma and Immunology, 2022 Program cell death protein 1 (PD1) is considered as an inhibitory molecule that is expressed on the surface of activated T-cells and bound to PD-L1 and PD-L2 ligands.
Azam Samei, Mostafa Khedri
doaj +3 more sources
The analgesic effect of programmed cell death protein-1. [PDF]
Korean J Pain, 2023 Park JY.
europepmc +3 more sources
Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer [PDF]
Annals of Translational Medicine, 2021 In recent years, immunotherapy has achieved notable success in cancer treatment. Indeed, the novel immune checkpoint lymphocyte activation gene-3 (LAG3) has shown promising therapeutic efficacy in non-small cell lung cancer. However, it is unclear about the role of LAG3 in immunotherapy and survival in small cell lung cancer (SCLC).The expression of ...
Sun, Hui +8 more
openaire +2 more sources
Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy. [PDF]
Genes (Basel)The ability to undergo neoangiogenesis is a common feature with all cancers. Signaling related to vascular endothelial growth factors (VEGF) and their receptors (VEGFR) plays a key role in the process of tumor neoangiogenesis. A close relationship has been demonstrated between excessive VEGF levels and the induction of immunosuppression in the tumor ...
Stachyra-Strawa P +4 more
europepmc +4 more sources